pali WKN: A4098S ISIN: US6963894026 Forum: Aktien User: Robo1976

Palisade Bio (Nasdaq: PALI) announced a strategic equity investment of up to $500,000 from the Crohn’s & Colitis Foundation through its IBD Ventures program to support development of PALI-2108, a gut-microbiota-activated PDE4 inhibitor designed for targeted delivery to the terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and moderate to severe ulcerative colitis (UC). Palisade has completed Phase 1a single- and multiple-ascending dose and food-effect studies, plus a Phase 1b cohort in UC, and is conducting a Phase 1b cohort in FSCD. Data from these studies are expected to support Phase 2 IND submissions to the FDA in 2026.